Epigenetics Market Size To Reach $39.15 Billion By 2030

Epigenetics Market Growth & Trends

The global epigenetics market size is expected to reach USD 39.15 billion by 2030, registering a CAGR of 15.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is being driven by factors, such as the rise in funding, investment & regulatory approvals for epigenetics research & development, the expansion of the use of epigenetic enzymes in drug discovery & development, and the decreasing cost of genome sequencing. Since epigenetics has demonstrated beneficial applications outside of cancer, commercial expansion is envisaged.The rising demand for understanding epigenetic alterations at the molecular level, as well as the advancement of medicinal treatments, would likely push these organizations to support research and development programs.

Furthermore, initiatives, such as the Epidemiology and Genomics Research Program (EGRP), provide incentives for research efforts aimed at better-comprehending cancer genesis and consequences.A few organizations that help fuel the market's rise are the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institutes of Health (NIH). These organizations support funding and help for initiatives involving product development and R&D in the field of epigenetics. For instance, the National Institutes of Health aggressively promotes cutting-edge epigenetic research worldwide through its common fund epigenomics program.

 Request a free sample copy or view report summary: Epigenetics Market Report

Epigenetics Market Report Highlights

• By product, the reagents segment dominated the industry, accounting for 33.45% of the global revenue in 2023. The large share of this segment can be attributed to the high usage of reagents in epigenetic research studies.

• By technology, the DNA methylation segment dominated the market with a revenue share of 45.36% in 2023. DNA methylation's demand in epigenetics stems from its pivotal role in gene expression regulation.

• By application, the oncology segment dominated the market with a revenue share of 69.06% in 2023. Oncology's demand for epigenetics arises from the intricate relationship between epigenetic alterations and cancer development.

• North America dominated the market and accounted for a 38.19% share in 2023. The region experiences growth due to heightened public awareness, robust medical facilities, and substantial R&D investments.

Epigenetics Market Segmentation

Grand View Research has segmented the global epigenetics market on the basis of product, technology, application, end-use, and region:

Epigenetics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagents

• Kits

  • ChIP sequencing kit

  • Whole Genomic Amplification kit

  • Bisulfite Conversion kit

  • RNA sequencing kit

  • Others

• Instruments

• Enzymes

• Services

Epigenetics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• DNA Methylation

• Histone Methylation

• Histone Acetylation

• Large non-coding RNA

• MicroRNA modification

• Chromatin structures

Epigenetics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

  • Solid tumors

  • Liquid tumors

• Non-oncology oncology

  • Inflammatory diseases

  • Metabolic diseases

  • Infectious diseases

  • Cardiovascular diseases

  • Others

Epigenetics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Academic Research

• Clinical Research

• Hospitals & Clinics

• Pharmaceutical & Biotechnology Companies

• Other Users

Epigenetics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

 List of Key Players of Epigenetics Market

• Roche Diagnostics

• Thermo Fisher Scientific, Inc.

• Eisai Co. Ltd.

• Novartis AG

• Element Biosciences, Inc.

• Dovetail Genomics LLC.

• Illumina, Inc.

• Promega Corporation.

• Abcam plc.